| |

A Guide to SAHPRA Submissions in South Africa for Pharma

Bytimiade

A Practical Guide to SAHPRA Submissions in South Africa

As the most developed economy in Southern Africa, South Africa is a critical market for pharmaceutical and biotech companies. The regulatory body, the South African Health Products Regulatory Authority (SAHPRA), has undergone significant transformation, moving away from the old MCC framework to a more modern, efficient system.

Understanding SAHPRA’s specific requirements is essential for a timely and successful registration. This guide outlines the key considerations for your submission.

Key Requirements Before You Submit

Before your dossier is submitted, SAHPRA requires several key pieces of information and legal appointments to be in place.

  • Appoint a Local Applicant: You must appoint a South African entity (a company registered in South Africa) to act as the legal “Applicant” and holder of the registration.
  • Establish a Local Responsible Pharmacist (RP): This Applicant must employ or contract a Responsible Pharmacist, who is registered with the South African Pharmacy Council (SAPC) and is legally accountable for the product.
  • GMP Certification: The manufacturing site(s) must have valid, acceptable GMP (Good Manufacturing Practice) certification. SAHPRA places strong emphasis on GMP and may require a SAHPRA-specific audit or a desktop review via a reliance pathway.
  • CTD/eCTD Format: SAHPRA has fully adopted the Common Technical Document (CTD) format for all new applications. Electronic submissions (eCTD) are becoming the standard and are strongly encouraged.

The SAHPRA Submission Process: An Overview

Upon submission, the application undergoes an administrative screening. SAHPRA checks that all required administrative documents, fees, and dossier modules are present and correctly formatted. An incomplete application will be rejected before any scientific review begins.

Once validated, the dossier enters the queue for full scientific review of its quality (CMC), safety (non-clinical), and efficacy (clinical) data. Historically, this has been a lengthy process, which is why SAHPRA’s reliance pathways are so important.

To accelerate access, SAHPRA has a ‘reliance’ pathway. If your product is already approved by a Stringent Regulatory Authority (SRA) like the EMA, MHRA, or FDA, SAHPRA can ‘rely’ on their assessment report. This can dramatically shorten review timelines from years to a matter of months.

Following a successful scientific review, SAHPRA will issue a registration certificate. The product will also be ‘scheduled’ (e.g., Schedule 1, 2, 3…) which determines how it can be sold and dispensed in South Africa.

Common Challenges to Avoid

  • Not Using the Reliance Pathway: Failing to leverage an existing approval from an SRA is the biggest missed opportunity, leading to a much longer review time.
  • Dossier Formatting: Submitting in an outdated (non-CTD) format or with eCTD formatting errors will lead to immediate rejection at the screening stage.
  • GMP Compliance Issues: Any ambiguity or out-of-date information regarding your manufacturing site’s GMP status will cause significant delays.

Planning Your Entry into South Africa?

Book Free Consultation

A successful SAHPRA submission requires a modern strategy, leveraging reliance pathways and flawless eCTD preparation. TEDDZ Regulatory has the expertise to guide your South African registration efficiently.

Similar Posts